[go: up one dir, main page]

AU2001291526A1 - Sustained release composition containing clarithromycin - Google Patents

Sustained release composition containing clarithromycin

Info

Publication number
AU2001291526A1
AU2001291526A1 AU2001291526A AU9152601A AU2001291526A1 AU 2001291526 A1 AU2001291526 A1 AU 2001291526A1 AU 2001291526 A AU2001291526 A AU 2001291526A AU 9152601 A AU9152601 A AU 9152601A AU 2001291526 A1 AU2001291526 A1 AU 2001291526A1
Authority
AU
Australia
Prior art keywords
sustained release
clarithromycin
release composition
composition containing
containing clarithromycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001291526A
Inventor
Philippe Baudier
Antonio Sereno
Francis Vanderbist
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galephar MF
Original Assignee
Galephar MF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galephar MF filed Critical Galephar MF
Publication of AU2001291526A1 publication Critical patent/AU2001291526A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

A pharmaceutical oral sustained release composition of clarithromycin containing coated pellets comprising each a core containing clarithromycin and a sustained release coating surrounding the core, in which the sustained release coating comprises at least a water insoluble polymer which is substantially pH independent. Disclosed is a method of treating infection including a sustained release oral form of CLARITHROMYCIN constituted by coated pellets and allowing a once a day administration of the drug.
AU2001291526A 2000-09-22 2001-09-21 Sustained release composition containing clarithromycin Abandoned AU2001291526A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE0000112 2000-09-22
AU73964/00 2000-09-22
PCT/BE2001/000164 WO2002024174A2 (en) 2000-09-22 2001-09-21 Sustained release composition containing clarithromycin

Publications (1)

Publication Number Publication Date
AU2001291526A1 true AU2001291526A1 (en) 2002-04-02

Family

ID=3862551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001291526A Abandoned AU2001291526A1 (en) 2000-09-22 2001-09-21 Sustained release composition containing clarithromycin

Country Status (9)

Country Link
US (1) US20040048814A1 (en)
EP (1) EP1318792B1 (en)
AT (1) ATE286387T1 (en)
AU (1) AU2001291526A1 (en)
CA (1) CA2423172A1 (en)
DE (1) DE60108255T2 (en)
ES (1) ES2234885T3 (en)
PT (1) PT1318792E (en)
WO (1) WO2002024174A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2003037304A1 (en) * 2001-11-02 2003-05-08 Wockhardt Limited Controlled release compositions for macrolide antimicrobial agents
US7137696B2 (en) * 2003-01-09 2006-11-21 Con-Trol-Cure, Inc. Ink jet UV curing
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
CA2533358C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528189A (en) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic products, their use and formulation
US8313775B2 (en) * 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
JP2007502296A (en) * 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Robust pellet
WO2005016278A2 (en) 2003-08-12 2005-02-24 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
EP1658034A4 (en) * 2003-08-29 2011-06-22 Middlebrook Pharmaceuticals Inc Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
BRPI0417348A (en) 2003-12-04 2007-03-13 Pfizer Prod Inc spray gelatinization process using an extruder for preparing multiparticulate crystalline drug compositions preferably containing a poloxamer and a glyceride
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
KR101122096B1 (en) * 2004-05-20 2012-03-15 주식회사종근당 Pharmaceutical composition of clarithromycin and its manufacturing method for taste masking and increasing dissolution rate
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
CN1322866C (en) * 2004-10-12 2007-06-27 广州贝氏药业有限公司 A multi-unit sustained-release preparation
FR2879075B1 (en) * 2004-12-15 2007-01-19 Adisseo France Sas Soc Par Act PROCESS FOR PREPARING EXTRUSION-ACTIVE HYDROPHILIC ACTIVE INGREDIENT PELLETS
JP2008525313A (en) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-dementia drug stabilization method
KR100676075B1 (en) 2005-02-17 2007-02-01 한국유나이티드제약 주식회사 Claricemicin-containing pellet preparations for oral administration
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US293885A (en) * 1884-02-19 Milton jackson
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
MX9603480A (en) * 1994-02-16 1997-12-31 Abbott Lab Process for preparing fine particle pharmaceutical formulations.
AUPO637197A0 (en) * 1997-04-23 1997-05-15 F.H. Faulding & Co. Limited Taste-masked pharmaceutical compositions
WO2001035930A1 (en) * 1999-11-16 2001-05-25 Ranbaxy Laboratories Limited Taste masked oral compositions
US6623757B2 (en) * 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition

Also Published As

Publication number Publication date
DE60108255T2 (en) 2005-12-22
ATE286387T1 (en) 2005-01-15
EP1318792A2 (en) 2003-06-18
DE60108255D1 (en) 2005-02-10
ES2234885T3 (en) 2005-07-01
PT1318792E (en) 2005-04-29
WO2002024174A3 (en) 2002-09-26
CA2423172A1 (en) 2002-03-28
EP1318792B1 (en) 2005-01-05
WO2002024174A2 (en) 2002-03-28
US20040048814A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
AU2001291526A1 (en) Sustained release composition containing clarithromycin
YU35302A (en) Hidrogel-driven drug dosage form
AP2001002237A0 (en) Hydrogel-driven drug dosage form.
YU36700A (en) Oral pharmaceutical extended release dosage form
WO2003028660A3 (en) Drug delivery devices and methods
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
WO2001008661A3 (en) Opioid sustained-released formulation
AU1534699A (en) Osmotic dosage form comprising first and second coats
IS4146A (en) A pharmaceutical preparation for oral administration of proton pump blockers
GEP20053602B (en) Aripiprazole for Oral Administration
AU6042796A (en) Controlled release formulation having a preformed passageway
HK1042427A1 (en) Sustained release matrix systems for highly soluble drugs
CA2411277A1 (en) Neurotoxin implant
CA2193129A1 (en) Transdermal drug delivery system
CA2298238A1 (en) Controlled release by extrusion of solid amorphous dispersions of drugs
AU2002254036A1 (en) Taste masked pharmaceutical compositions
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
AU2084801A (en) Antiviral medication
NO20101070L (en) Method of dosing a drug, as well as dosage form
ES2130081A1 (en) Coated trimebutine maleate tablet
CA2383212A1 (en) Controlled release oral dosage suitable for oral administration
AU3071300A (en) Multiparticulate bisoprolol formulation
DE69627365D1 (en) DELAYED RELEASE ADMINISTRATION SYSTEM AND LONG-TERM NARCOTIC ANALGES AND ANTAGONISTS
WO2001060343A3 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers
ATE245974T1 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE ORAL ADMINISTRATION OF PHLOROGLUCINOL AND THE PRODUCTION THEREOF